To the Editor In JAMA Psychiatry, Jones and colleagues report compelling phase 2 data on TSND-201, suggesting rapid and durable reductions in posttraumatic stress disorder (PTSD) symptoms after a brief, intermittent dosing regimen. Several aspects of the trial design raise questions that may help readers more fully contextualize the observed effects.